Imago Biosciences, Inc.

Ferrokin Biosciences, Inc.

Amy E Tapper

Hugh Young Rienhoff, Jr

Cassandra Celatka

Michael John Clare

John Michael McCall

Stephan D Parent

Patricia Andres

Jason A Hanko

Huamin Zhang

Arthur Glenn Romero

He Zhao

Elisabeth C A Brot

Jian-Xie Chen

Xuemei Chen

Zhihua Li

Xiaoming Liao

Toni Chancellor

Betina Biolatto

John M Mccall

Hugh Young Rienhoff

Namrata Vora

Patricia Soulliac

Parag Ved

Jr Hugh Y Reinhoff

The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.

KDM1A inhibitors for the treatment of disease

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive animation of cyclopropylamines.

Methods and processes for the preparation of KDM1A inhibitors

Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogs, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents

Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Growing community of inventors

Boston, MA, United States of America

Amy E Tapper